Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -69,005 | -155,203 | -92,673 | -81,490 | -44,773 |
| Accounts payable and accrued liabilities | -3,212 | 8,238 | 6,791 | 3,046 | 3,023 |
| Other Working Capital | 244 | -5,934 | -3,669 | -9,609 | -568 |
| Other Operating Activity | 14,601 | -16,353 | -35,123 | 496 | 1,324 |
| Operating Cash Flow | $-57,372 | $-169,252 | $-124,674 | $-87,557 | $-40,994 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 26,581 | -150,475 | 96,935 | 71,937 | -61 |
| Other Investing Activity | 30,000 | 7,000 | 7,000 | 7,000 | 0 |
| Investing Cash Flow | $56,581 | $-143,475 | $103,935 | $78,937 | $-61 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 9,750 | 314,438 | 1,557 | 1,066 | N/A |
| Other Financing Activity | 2,505 | -5,413 | -5,344 | -210 | 125 |
| Financing Cash Flow | $12,255 | $309,025 | $-3,787 | $856 | $125 |
| Beginning Cash Position | 85,721 | 89,423 | 89,423 | 89,423 | 89,423 |
| End Cash Position | 97,185 | 85,721 | 64,897 | 81,659 | 48,493 |
| Net Cash Flow | $11,464 | $-3,702 | $-24,526 | $-7,764 | $-40,930 |
| Free Cash Flow | |||||
| Operating Cash Flow | -57,372 | -169,252 | -124,674 | -87,557 | -40,994 |
| Free Cash Flow | -57,372 | -169,252 | -124,674 | -87,557 | -40,994 |